LLY Aug 2024 670.000 put
| Previous close | 11.55 |
| Open | 8.50 |
| Bid | 7.90 |
| Ask | 8.30 |
| Strike | 670.00 |
| Expiry date | 2024-08-16 |
| Day's range | 8.50 - 8.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 35 |
ZacksShould You Hold Viking Therapeutics (VKTX) in Your Portfolio?
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
Investor's Business DailyIs Eli Lilly Stock A Buy Or A Sell With Key Alzheimer's Meeting Looming?
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?
- Reuters
UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down
Britain's Pharmacy2U said on Wednesday it had cut the prices of weight-loss medication Wegovy and Mounjaro, becoming the latest in a slew of online pharmacies and slimming clinics to do so as initial supply shortages of the drugs ease in the country. The British market could provide a glimpse into how the fight for patients among private suppliers could develop as drugmakers Novo Nordisk and Eli Lilly ramp up production. Growing competition between retailers has raised fears that some patients who buy the drugs themselves, amid limited capacity of the National Health Service, will miss out on long-term aftercare if they keep switching providers.
